Země: Izrael
Jazyk: angličtina
Zdroj: Ministry of Health
TRANEXAMIC ACID
TEVA ISRAEL LTD
B02AA02
TABLETS
TRANEXAMIC ACID 500 MG
PER OS
Required
TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL
TRANEXAMIC ACID
TRANEXAMIC ACID
Treatment of hemorrhage occuring in some forms of surgery, including prostatectomy. Hematuria. Menorrhagia. Hereditary angioneurotic edema.
2021-05-31
عباط صيخشت بجي !ةمتعلا يف ةيودأ لوانت زوجي لا اهيف لوانتت ةرم لك يف يئاودلا رادقملا نم دكأتلاو ءاودلا .كلذ رملأا مزل اذإ ةيبطلا تاراظنلا عض .ءاود ،ءاودلا اذه لامعتسإ لوح ةيفاضإ ةلئسأ كيدل ترفوت اذإ .يلديصلا وأ بيبطلا رشتسإ ةيبناجلا ضارعلأا )4 ً اضارعأ ببسي دق نورپاكاسكه لامعتسإ نإ ،ءاود لكب امك ضارعلأا ةمئاق نم شهدنت لا .نيلمعتسملا ضعب دنع ةيبناج .اهنم ً ايأ يناعت لاأ زئاجلا نم .ةيبناجلا نينيعلا يف تابارطضإ نيلمعتسم 1-10 ىدل رهظت ضارعأ( ةردان ةيبناج ضارعأ :)10٫000 نيب نم ناوللأا ةيؤر يف ةصاخ ،ةيؤرلا يف لكاشم ● نيعلا يف فزن رملأا اذه ببسي دق .نيعلا يف ةيومد ةرثخ ● ةيؤرلا نادقف وأ يعانملا زاهجلا يف تابارطضإ نم لقأ ىدل رهظت ضارعأ( ً ادج ةردان ةيبناج ضارعأ :)10٫000 نيب نم 1 لمعتسم سفنتلا يف ةبوعص ىلإ يدؤت يتلا ةيسسحت لعف دودر لمشت ● راود ىلإ وأ ةيومدلا ةيعولأا يف تابارطضإ نم لقأ ىدل رهظت ضارعأ( ً ادج ةردان ةيبناج ضارعأ :)10٫000 نيب نم 1 لمعتسم ـ راثخ ةلاحلا هذه ىمست( ةيومدلا ةيعولأا يف ةيومد ةرثخ ● ) thrombosis يمضهلا زاهجلا يف تابارطضإ نم لقأ ىدل رهظت ضارعأ( ً ادج ةردان ةيبناج ضارعأ :)10٫000 نيب نم 1 لمعتسم نايثغ ● ؤيقت ● لاهسإ ● ، ً ادج ً اعيرس لوزتو ةفيفط نوكت ةداع ةيبناجلا ضارعلأا هذه .كلذ نع يلديصلا وأ كبيبطل كحإ ،ترمتسإ اذإ نكل دلجلا تحت جيس Přečtěte si celý dokument
Hexakapron Tablets OKD 08/2023 Notification SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Hexakapron Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains Tranexamic acid 500 mg as the active ingredient. Excipient with known effect: Each tablet contains 0.504-0.756 mg of sodium. For excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablets. White, round flat beveled tablet engraved "TEVA" on one side and bisecting line on the other. The tablet can be divided into equal halves. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications Treatment of hemorrhage occurring in some forms of surgery, including prostatectomy. Hematuria. Menorrhagia. Hereditary angioneurotic edema. 4.2 Posology and method of administration Dosage and Administration Doses should be reduced in renal impairment. Adults The recommended standard dosage is 2-3 tablets, 2-3 times daily . For the indications listed below, specific recommendations are made as follows: (please refer also to the Physicians’ Prescribing Information for Hexakapron injection) Prostatectomy Following I.V. administration (refer to the Physicians’ Prescribing Information for the injection), 2-3 Hexakapron tablets, 2-3 times daily, until macroscopic hematuria is no longer present. Dental Surgery Factor VIII or IX concentrates and Hexakapron 10 mg/kg body weight should be administered intravenously immediately before surgery. Following surgery, 25 mg/kg body weight should be administered orally, 3-4 times daily, for 6-8 days. As a rule, it is not necessary to administer factor VIII or IX concentrates following surgery . Hematuria 2-3 tablets, 2-3 times daily, until macroscopic hematuria is no longer present. Hexakapron Tablets OKD 08/2023 Notification Menorrhagia 2-3 tablets, 3-4 times daily, for 3-4 days. Hexakapron therapy should be initiated only after heavy bleeding has started. Use of the drug should be restricted to not more than three menstrual cycles . Hereditary Angioneurotic Edema Some patients are aware of the onset of the illn Přečtěte si celý dokument